NEWS DETAIL

Genetic Analysis as and Thalys Medical Technology Group Enter Microbiome Laboratory Developed Test (LDT) Agreement for the Chinese Market

OSLO, NORWAY/SHANGHAI, CHINA – 13. January 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Thalys Medical Technology Group Corporation (“Thalys”) announces today that the parties have entered a Laboratory Developed Test (LDT) agreement to evaluate and develop innovative diagnostic solutions for the rapidly growing human microbiota market in China. Thalys will use its Shanghai-based Medical Lab group to further develop and distribute tests based on Genetic Analysis's GA-map® technology.

Over the recent years, the Chinese human microbiome market has been witnessing considerable growth on the back of rising incidences of diabetes, a growing geriatric population, and the continuous research and development being conducted by pharmaceutical manufacturers and academia. Latest forecasts* suggests the global human microbiome market to grow at a rate of 22.5% over the period 2022 to 2029 reaching USD 965.59 million by 2029. Along with the US, China is predicted to be one of the main contributors accelerating both in terms of evidence-based research and launched pharma products. In parallel, there is growing demand for clinically validated microbiome tests. The overall prevalence of IBS (Irritable Bowel Syndrome) in China ranges from 1.4% to 11.5%, however, China Expert Consensus of IBS (2020) pointed out that the prevalence of IBS may be highly underestimated. For the severe intestinal disease IBD (Inflammatory Bowel Disease), the total number of cases in China is estimated to reach 1.5 million by 2025.

In the first stage of the collaboration, Thalys Group will use its newly built Shanghai-based Independent Clinical Lab (ICL), Thalys MedLab to further develop and distribute tests based on Genetic Analysis' GA-map® Technology in China. In 2021, Genetic Analysis launched the updated version of GA-map® Dysbiosis Test – the first CE-marked IVD test on the market providing microbiota profiles and dysbiosis status for IBS and IBD patients. The GA-map® Technology platform itself is based on an innovative Pre-Determined Targets approach (PDT).